drugset / Trial / NCT02114528

Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention

NCT02114528

Phase 4 Terminated 3 enrolled Ottawa Heart Institute Research Corporation
RandomizedParallel-groupTreatment

Summary

The purpose of this study is to determine whether catheter based ablation is better than conventional anti-arrhythmic drug (AAD) therapy for reducing recurrent shocks in patients with an implantable cardioverter defibrillator (ICD). The second purpose of the study is to determine the safety of catheter-based ablation and the effect on quality of life of patients. The study hypothesis is that catheter ablation is superior to AAD therapy in preventing recurrent ventricular arrhythmia in such subjects. This is a pilot trial which will provide data regarding recruitment potential and the feasibility of conducting a larger trial.

Timeline

Start
2014-10
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amiodarone Small molecule 200 mg Oral
Comparator Mexiletine Small molecule Oral
Comparator Procainamide Small molecule Oral
Comparator sotalol Small molecule Oral